Daily Endocrinology Research Analysis
Three impactful endocrinology papers stand out today: a randomized trial shows semaglutide improves walking capacity in PAD with type 2 diabetes across BMI/HbA1c strata; a five-year real-world registry supports the safety and sustained height gains of long-acting PEGylated growth hormone in pediatric GHD; and a network meta-analysis suggests no significant increase in fracture risk with antidiabetic agents versus placebo while assessing bone density effects.
Summary
Three impactful endocrinology papers stand out today: a randomized trial shows semaglutide improves walking capacity in PAD with type 2 diabetes across BMI/HbA1c strata; a five-year real-world registry supports the safety and sustained height gains of long-acting PEGylated growth hormone in pediatric GHD; and a network meta-analysis suggests no significant increase in fracture risk with antidiabetic agents versus placebo while assessing bone density effects.
Research Themes
- GLP-1 receptor agonists improve functional outcomes beyond glycemic/weight effects
- Long-acting growth hormone real-world long-term safety and efficacy
- Skeletal safety of antidiabetic therapies in type 2 diabetes
Selected Articles
1. Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial.
In STRIDE (n=792), once-weekly semaglutide 1.0 mg improved maximum and pain-free walking distances at 52 weeks across subgroups defined by diabetes duration, BMI, HbA1c, and concomitant therapies. Interaction tests were non-significant, and benefits appeared independent of weight or glycemic changes; safety was consistent.
Impact: This RCT demonstrates functional benefits of semaglutide in PAD with T2D irrespective of BMI or glycemic control, expanding its utility beyond weight and HbA1c reduction.
Clinical Implications: Consider semaglutide to improve functional capacity in PAD with T2D even in non-obese patients and those with well-controlled HbA1c; benefits are consistent across common diabetes subgroups.
Key Findings
- Semaglutide improved maximum walking distance at 52 weeks across all subgroups (ETR ~1.12–1.16; no significant interaction).
- Pain-free walking distance improved uniformly with non-significant interaction tests (P > 0.1).
- BMI reduction correlated only weakly with MWD improvement; benefits persisted in those without obesity and with HbA1c <7%.
- Safety outcomes were consistent across subgroups.
Methodological Strengths
- Randomized, double-blind, placebo-controlled design with consistent outcome assessment at 52 weeks.
- Predefined subgroup analyses with mixed models for repeated measures and interaction testing.
Limitations
- Subgroup analyses may be underpowered to detect interactions.
- Functional outcomes assessed by treadmill tests rather than hard cardiovascular endpoints.
Future Directions: Evaluate long-term cardiovascular and limb outcomes and mechanistic pathways mediating functional gains independent of weight/glycemia.
OBJECTIVE: The Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE) trial (NCT04560998) showed that once-weekly subcutaneous semaglutide 1.0 mg significantly improved functional outcomes, symptoms, and quality of life in individuals with symptomatic peripheral artery disease (PAD) and type 2 diabetes. Whether these benefits are consistent across diabetes-related characteristics remains unclear. RESEARCH DESIGN AND METHODS: The primary outcome was the ratio to baseline (ETR) in maximum walking distance (MWD), with pain-free walking distance (PFWD) as a key secondary end point. Both were measured at 52 weeks using a constant load treadmill. Subgroup analyses were performed by diabetes duration, BMI, HbA1c, and diabetes medications. A mixed model for repeated measurements was used, incorporating treatment, region, and subgroup as fixed factors, and baseline value as covariate, along with the treatment-by-subgroup interaction. RESULTS: Among 792 participants (median diabetes duration 12.2 years, HbA1c 7.1%, and BMI 28.7 kg/m2), 35.1% used sodium-glucose cotransporter 2 inhibitors and 31.7% used insulin. Semaglutide significantly improved MWD regardless of diabetes duration (ETR of 1.15 vs. 1.13 for <10 vs. ≥10 years, P = 0.80), BMI (1.12 vs. 1.16 for <30 vs. ≥30 kg/m2, P = 0.58), HbA1c (1.13 for <7% and ≥7%, P = 0.99), or medication use. Semaglutide also improved PFWD across subgroups (P > 0.1 for all interactions). BMI reduction correlated weakly with MWD improvements and was more pronounced in the control individuals with higher baseline BMI. Safety outcomes were consistent across subgroups. CONCLUSIONS: Semaglutide improved walking function in people with PAD and type 2 diabetes, including individuals without obesity and those with well-controlled HbA1c. Benefits were consistent across BMI and HbA1c categories, supporting effectiveness beyond weight or glycemic changes.
2. Evaluation of bone health and fracture risk in type 2 diabetes: a network meta-analysis of anti-diabetic treatments versus placebo.
Across 242 studies (n=234,759), antidiabetic therapies showed a non-significant trend toward reduced fracture risk versus placebo (OR 0.92, 95% CI 0.84–1.01). Bone mineral density outcomes were assessed by treatment class, and subgroup analyses by treatment duration were performed.
Impact: This registered network meta-analysis synthesizes large-scale evidence on skeletal outcomes across antidiabetic classes, addressing a key safety concern in diabetes management.
Clinical Implications: Current pooled evidence does not indicate a significant overall increase in fracture risk with antidiabetic agents versus placebo, supporting individualized therapy without generalized concern for fractures, while continuing bone health monitoring.
Key Findings
- Network meta-analysis included 242 studies with 234,759 participants.
- Overall, antidiabetic treatments showed a non-significant trend toward lower fracture risk vs placebo (OR 0.92, 95% CI 0.84–1.01).
- Bone mineral density differences were analyzed by treatment class, with subgroup analyses by treatment duration.
- Protocol registration (CRD42024538789) and comprehensive databases (PubMed, Embase, ClinicalTrials.gov) support methodological rigor.
Methodological Strengths
- Registered protocol and adherence to systematic search across multiple databases.
- Large aggregated sample with random-effects modeling and subgroup analyses.
Limitations
- Non-significant primary pooled effect; potential heterogeneity and class-specific effects not fully resolvable from the abstract.
- Details on site-specific fractures and BMD changes per class are limited in the reported summary.
Future Directions: Clarify class- and site-specific fracture risks and BMD trajectories with individual patient data meta-analyses and longer follow-up.
While studies have highlighted the negative effects of certain antidiabetic agents, similar evidence for other antidiabetic agents remains limited. In this study, we aimed to analyze bone fractures and bone mineral densities (BMDs) across patients receiving antidiabetic treatments, considering both overall and specific sites. We comprehensively searched PubMed, Embase, and ClinicalTrials.gov up to March 2024 to determine the effect of antidiabetic agent use on bone health in patients with type 2 diabetes mellitus. The primary outcome was to reveal variations in fractures across different anti-diabetic treatment modalities. The secondary outcome was the differences in BMDs based on treatment type. The fractures were grouped based on the division of specific sites. We also performed a subgroup analysis to identify differences between treatment types by dividing the study by treatment duration. The protocol is registered (CRD42024538789). A total of 234,759 individuals were enrolled in the 242 studies. We observed a trend wherein all anti-diabetic treatments were associated with decreased risk of fracture compared with placebo; however, this was not significant in direct analysis (OR 0.92, 95% CI 0.84-1.01, I
3. Five-year safety and growth response of long-acting PEGylated recombinant human growth hormone in children with growth hormone deficiency-data from CGLS database.
In a large Chinese real-world registry, PEGylated long-acting rhGH showed an acceptable safety profile (AEs 46.6%; SAEs 1.0%, none treatment-related) and sustained height gains (mean ΔHt SDS +2.1±0.9 over 5 years) in pediatric GHD, with younger children responding better.
Impact: Provides rare 5-year real-world safety and efficacy data for long-acting GH therapy in pediatric GHD, informing long-term treatment decisions.
Clinical Implications: Supports the long-term use of PEGylated rhGH in pediatric GHD with ongoing safety monitoring; earlier initiation may maximize growth outcomes.
Key Findings
- Safety set included 1,207 children; 339 received continuous PEG-rhGH for 5 years for efficacy assessment.
- Adverse events occurred in 46.6% (1,328 AEs); serious AEs in 1.0% (n=12), none related to PEG-rhGH.
- Mean height SDS increased by +2.1±0.9 over 5 years; younger participants showed more favorable responses.
Methodological Strengths
- Large real-world surveillance registry with 5-year follow-up.
- Concurrent assessment of safety (AEs/SAEs) and growth efficacy (height SDS).
Limitations
- Observational design without a randomized comparator introduces potential confounding and selection bias.
- Single-country data and product-specific (Jintrolong) limits generalizability.
Future Directions: Comparative effectiveness studies versus daily rhGH and across long-acting GH formulations, with endocrine/metabolic safety endpoints.
UNLABELLED: Growth hormone deficiency (GHD) is an endocrine disorder characterized by insufficient production of growth hormone (GH). PEGylated recombinant human growth hormone (PEG-rhGH; Jintrolong®, GeneScience Pharmaceuticals Co., Ltd.) is the only long-acting GH approved in China for treating paediatric GHD (PGHD). Long-term Efficacy and Safety Evaluation of Growth Hormone in Children in China (CGLS) is a large, surveillance registry database of participants with short stature treated with PEG-rhGH or rhGH in a real-world setting. In this study, we evaluated the safety profile and five-year growth response of PEG-rhGH based on the data from the CGLS database in participants with PGHD in China. In this real-world registry-based observational study, a total of 1,207 participants were included in the safety analysis set. Of these, 339 participants who had received PEG-rhGH continuously for five years were also included in the efficacy analysis. Key outcomes assessed comprised adverse events (AEs), serious AEs (SAEs), and height gain. The safety assessment indicated that 563 participants exhibited 1328 AEs with an incidence rate of 46.6%. Furthermore, SAEs occurred in 1.0% of participants (n = 12), with none of them associated with PEG-rhGH treatment. A significant increase in mean change in height-SD score (∆Ht SDS) was observed during the treatment period, with a mean ∆Ht SDS of 2.1 ± 0.9 in five years. Subgroup analysis showed that the younger participants exhibited a more favourable response to therapy. CONCLUSION: CGLS data showed that five-year PEG-rhGH treatment in children with PGHD was associated with a favourable safety profile and sustained height gain. WHAT IS KNOWN: • Several long-acting growth hormones (LAGH) have been approved for use in PGHD. PEGylated recombinant growth hormone (PEG-rhGH) is the only LAGH marketed in China, with its three-year efficacy and safety have been reported. WHAT IS NEW: • Data from the CGLS database confirms that PEG-rhGh has an acceptable safety profile over five years, with significant improvement in height. Importantly, the data indicate that initiating the treatment earlier yields better outcomes.